Two Ebola therapies best ZMapp in Congo trial
All patients in an Ebola trial in the Democratic Republic of the Congo will be offered treatments from Regeneron and NIAID after they were shown to be superior to ZMapp in preventing death in the PALM platform study.
Trial co-sponsors NIH and the Institut National de Recherche Biomédicale (INRB) said Monday they will stop the randomized, controlled trial early based on data that showed patients treated with REGN-EB3 from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and mAb114 from the National Institute of Allergy and Infectious Diseases Vaccine Research Center had a greater chance of survival compared with the control, ZMapp from Mapp Biopharmaceutical Inc. (San Diego, Calif.). The trial also tested a fourth therapy, remdesivir (GS-5734) from Gilead Sciences Inc. (NASDAQ:GILD)...